A Study for Patients With Rheumatoid Arthritis on Methotrexate (MTX) With an Inadequate Response to TNFα Inhibitor Therapy
Status: | Completed |
---|---|
Conditions: | Arthritis, Rheumatoid Arthritis |
Therapuetic Areas: | Rheumatology |
Healthy: | No |
Age Range: | 18 - 75 |
Updated: | 12/8/2018 |
Start Date: | June 2008 |
End Date: | May 2010 |
A Phase 2 Study of Multiple Intravenous Doses of LY2127399 in Patients With Rheumatoid Arthritis on Concomitant Methotrexate and an Inadequate Response to TNFα Inhibitor Therapy
The purpose of this study is to explore whether LY2127399 is effective in relieving signs and
symptoms of rheumatoid arthritis (RA) in patients with a history of inadequate response or
intolerance to at least 1 Tumor Necrosis Factor-Alpha (TNFα) inhibitor therapy. Examples of
these TNFα inhibitor therapies that are currently on the market include Enbrel® (etanercept),
Remicade® (infliximab), and Humira® (adalimumab).
symptoms of rheumatoid arthritis (RA) in patients with a history of inadequate response or
intolerance to at least 1 Tumor Necrosis Factor-Alpha (TNFα) inhibitor therapy. Examples of
these TNFα inhibitor therapies that are currently on the market include Enbrel® (etanercept),
Remicade® (infliximab), and Humira® (adalimumab).
Inclusion Criteria:
- Have given written informed consent approval
- Women must not be at risk to become pregnant during study participation
- Diagnosis of Rheumatoid Arthritis
- Active Rheumatoid Arthritis
- Current, regular use of Methotrexate, at a stable dose
- Have been on at least 1 biologic tumor necrosis factor-alpha (TNFα) inhibitor therapy
and either failed or were intolerant to treatment
- Other criteria to be reviewed by study doctor
Exclusion Criteria:
- Use of excluded medications (reviewed by study doctor)
- Have medical findings which, in the opinion of the study doctor, put patient at an
unacceptable risk for participation in the study
- Have had recent or ongoing infection which, in the opinion of the study doctor put
patient at an unacceptable risk for participation
- Evidence of tuberculosis
- Have systemic inflammatory condition other than rheumatoid arthritis (RA), such as
juvenile RA, seronegative spondyloarthropathy, Crohn's disease, ulcerative colitis, or
psoriatic arthritis.
- Other criteria to be reviewed by study doctor
We found this trial at
20
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials